Derick Peterson, PhD

Associate Professor of Biostatistics and Computational Biology
Director, Biostatistics Shared Resource for the James P. Wilmot Cancer Center


 

Contact Information:

University of Rochester
Dept of Biostatistics and Computational Biology
601 Elmwood Avenue Box 630
Rochester, New York 14642
 
Office: Saunders Research Building 4220
Phone: (585) 275-6686
Fax: (585) 273-1031
E-mail: Peterson (at) bst.rochester.edu
Derick Peterson, PhD

Research Interests

Methodological research topics of particular interest to me include the construction of prognostic gene expression profiles from high-dimensional microarray data, model selection, nonparametric estimation and inference, data-driven smoothing methods, and the analysis of censored survival data.

My experience in applied medical & epidemiological research includes collaborative work on Long-QT Syndrome (Heart Research), the Program of All-Inclusive Care for the Elderly (Community & Preventive Medicine), Respiratory Syncytial Virus (Infectious Diseases), HIV & cognitive functioning (Neurology), bioterrorism detection (Monroe County Health Department), and cancer research.

Currently, I am developing novel methods for the construction of prognostic gene expression profiles based on censored survival and high-dimensional microarray data for breast cancer patients. My goal is to move beyond the limited univariate methods most often employed for selecting genes and make some use of the multivariate structure of the correlated gene expressions as well as important clinical covariates.

I joined the Biostatistics faculty at the University of Rochester in 1998, directly after receiving my PhD in Biostatistics from UC-Berkeley, under the supervision of Prof. Mark J. van der Laan and Prof. Kjell A. Doksum.

Technical reports

  • Peterson, D. (2006). Constructing Multivariate Prognostic Gene Signatures with Censored Survival Data. (Technical Report 06/09).

Selected Publications

Statistical Methods

  • Peterson, DR (2012).  “Constructing multivariate prognostic gene signatures with censored survival data” (Chapter 4), in Methods in Molecular Biology:  Statistical Methods for Microarray Data (to appear July 2013; Tentative volume 2246; ISBN: 978-1-60327-336-7).  Yakovlev, AY, Klebanev, L, and Gaile, D (Editors).  Humana Press Inc, Totowa, NJ.
  • Oakes, D. and Peterson, D.R. (2008). Survival methods: Additional topics. Circulation 117:2949-2955.
  • Peterson, D.R., Zhao, H., and Eapen, S. (2003). Using local correlation in kernel-based smoothers for dependent data. Biometrics 59:984-991.
  • Doksum, K., Peterson, D., and Samarov, A. (2000). On variable bandwidth selection in local polynomial regression. Journal of the Royal Statistical Society, Series B (Statistical Methodology) 62:431-448.
  • van der Laan, M.J., Jewell, N.P., and Peterson, D.R. (1997). Efficient estimation of the lifetime and disease onset distribution. Biometrika 84:539-554.

Cancer Research

  • Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova MS, Beard C, Haugnes HS, Fossa SD, Oldenburg J, and Travis LB (2012).  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.  Journal of Clinical Oncology 30(3):300--307.  PMID:  22184390.  PMCID:  PMC3269954.
  • Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, and Fisher SG (2012).  Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.  Cancer 118(1):72--81.  doi: 10.1002/cncr.26238.  PMID: 21720989.
  • Menapace LA, Peterson DR, Berry A, Sousou T, and Khorana AA (2011).  Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer.  Thrombosis and Haemostasis (to appear 8/11). 
  • Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armtage JO, Grant S, and Leonard JP (2011).  The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin's lymphoma.  Blood 117(10):2807-2812.  doi:10.1182/blood-2010-11-314708.  PMID: 21239695. 
  • Fossa, SD, Cvancarova, M, Chen, L, Allan, AL, Oldenburg, J, Peterson, DR, and Travis, LB (2011).  Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients.  Journal of Clinical Oncology 29(8):963-970.  doi: 10.1200/JCO.2010.32.3204.  PMID: 21300926.
  • Friedberg JW, Kelly J, Neuberg D, Peterson D, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Rothberg P, Liesveld J, Fisher RI, Coffman R, Mosmann T, and Freedman AS (2009). Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology, DOI: 10.1111/j.1365-2141.2009.07773.x, 146(3):282-291, PMCID: PMC2747261.
  • Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D.R., Howard, D.S., and Jordan, C.T. (2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163-4169.

Heart Research

  • Barsheshet A, Peterson DR, Moss AJ, Schwartz P, Kaufman ES, McNitt S, Polonsky S, Buber J, Zareba W, Robinson JL, Ackerman MJ, Benhorin J, Towbin JA, Vincent GM, Zhang L, and Goldenberg I (2011).   Genotype-specific QT correction for heart rate and the risk of life threatening cardiac events in adolescents with the congenital Long-QT Syndrome.  Heart Rhythm PII: S1547-5271(11)00276-1.  doi:10.1016/j.hrthm.2011.03.009.
  • Lane, RD, Zareba, W, Reis, H, Peterson, DR, and Moss, AJ (2011).  Changes in ventricular repolarization duration during typical daily emotion in patients with Long QT Syndrome. Psychosomatic Medicine 73:98-105.  PMID: 21183717.
  • Liu, JF, Jons, C, Moss, AJ, McNitt, S, Peterson, DR, Qi, M, Zareba, W, Robinson, JL, Barshashet, A, Ackerman, MJ, Benhorin, J, Kaufman, ES, Locati, EH, Napolitano, C, Priori, SG, Schwartz, PJ, Towbin, J, Vincent, M, Zhang, L, Goldenberg, I; for the International Long QT Syndrome Registry (2011).  Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with Long QT Syndrome.  Journal of the American College of Cardiology 57:941-950, doi:10.1016/j.jacc.2010.10.025.
  • Lane, RD, Reis, HT, Peterson, DR, Zareba, W, and Moss, AJ (2009). Happiness and stress alter susceptibility to cardiac events in Long QT Syndrome. Annals of Noninvasive Electrocardiology 14:191-198.
  • Hobbs, J.B., Peterson, D.R., Moss, A.J., McNitt, S., Zareba, W., Goldenberg, I., Qi, M., Robinson, J.L., Sauer, A.J., Ackerman, M.J., Benhorin, J., Kaufman, E.S., Locati, E.H., Napolitano, C., Priori, S.G., Towbin, J.A., Vincent, G.M., and Zhang, L. (2006). Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the Long-QT Syntrome. Journal of the American Medical Association 296:1249-1254.
  • Moss, A.J., Peterson, D.R., Zareba, W., Seth, R., McNitt, S.A., Andrews, M.L., Ackerman, M.J., Benhorin, J., Kaufman, E.S., Napolitano, C., Priori, S.G., Robinson, J.L., Schwartz, P.J., Towbin, J.A., Vincent, G.M., and Zhang, L. (2005). Beta-blocker efficacy in Long QT Syndrome patients with mutations in the pore and nonpore regions of the hERG potassium-channel gene. New Arrhythmia Technologies. Wang, P., Naccarelli, G., Rosen, M., Estes, M., Hayes, D., and Haines, D., ed. Blackwell Publishing, Cambridge.
  • Zareba, W., Moss, A.J., Locati, E.H., Lehmann, M.H., Peterson, D.R., Hall, W.J., Schwartz, P.J., Vincent, G.M., Priori, S.G., Benhorin, J., Towbin, J.A., Robinson, J.L., Andrews, M.L., Napolitano, C., Timothy, K., Zhang, L., Medina, A. (2003). Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. Journal of the American College of Cardiology 42:103-109.
  • Moss, A.J., Zareba, W., Kaufman, E.S., Gartman, E., Peterson, D.R., et. al. (2002). Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the Human Ether-a-go-go-Related Gene potassium channel. Circulation 105:794-799.